Takeda Pharmaceutical Falls After Providing Changes On TAK-994 Clinical Program

For the last trading session, Takeda Pharmaceutical (TAK) stock has been showing negative change along with a 7% fall. The change was probably caused by the latest announcement that during the Phase 2 studies of TAK-994 a safety signal has emerged. After which the company has immediately stopped the dosing of patients and has decided to stop both Phase 2 studies early.

The company prioritizes the safety and health of patients participating in clinical studies. Takeda is grateful to all of the patients, physicians, and site staff who participated in these important clinical trials. Takeda’s main goal is to bring innovative, safe, and effective treatments for patients with narcolepsy. Takeda Neuroscience is driven by the unmet need of patients with neurologic and psychiatric diseases.